Skip to main content

Advertisement

SpringerLink
Log in

A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin and trastuzumab for T2 breast cancers

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Preclinical data indicate that the combination of docetaxel, cisplatin and trastuzumab (TCH) may have the potential for clinically significant activity against breast cancers that overexpress the her2/neu gene (HER2). An open-label phase II trial was designed to investigate the response rate and toxicity profile of TCH in breast cancer patients with a primary tumor 2–5 cm in diameter (T2) in its original size.

Methods

Thirty breast cancer patients with HER2-overexpressing tumors were enrolled. Patients received 6 cycles of docetaxel at 60 mg/m2 and cisplatin at 50 mg/m2 given on day 1 and then every 21 days. Trastuzumab was given on day 1, cycle 1 (4 mg/kg), and then continued weekly at 2 mg/kg for 1 year or until disease progression. Tumor measurements were obtained at baseline as well as after 3 and 6 cycles of chemotherapy.

Results

We identified 29 breast cancer patients in Taiwan, of whom 13 (44.8%) had pathological complete responses. No cardiac toxicity was observed. Hematologic grade 4 or 3 toxicities were observed in 1 of 28 patients. Non-hematologic grade 4 or 3 toxicities with a reverse pattern were observed in 6 of 29 patients.

Conclusions

The results of our study indicate that TCH neoadjuvant chemotherapy is feasible and active in T2 HER2-overexpressing breast cancer patients in terms of pathological complete response rate, complete response, partial response and manageable toxicities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275–1281

    Article  PubMed  Google Scholar 

  2. Ezzat AA, Ibrahim EM, Ajarim DS, Rahal MM, Raja MA, Tulbah AM, Al-Malik OA, Al-Shabanah M, Sorbris R (2004) Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients. Br J Cancer 90:968–974

    Article  PubMed  CAS  Google Scholar 

  3. Pegram MD, Pienkowski T, Northfelt DW, Eiermann W, Patel R, Fumoleau P, Quan E, Crown J, Toppmeyer D, Smylie M, Riva A, Blitz S, Press MF, Reese D, Lindsay MA, Slamon DJ (2004) Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 96:759–769

    Article  PubMed  CAS  Google Scholar 

  4. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23:3676–3685

    Article  PubMed  CAS  Google Scholar 

  5. Buzdar AU (2007) Adjuvant chemotherapy for high-risk operable breast cancer. J Clin Oncol 25:1642–1644

    Article  PubMed  CAS  Google Scholar 

  6. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju R, Valentine E, Sayre R, Cobleigh M, Albain K, McCullough C, Fuchs L, Slamon D (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24:2786–2792

    Article  PubMed  CAS  Google Scholar 

  7. Coudert BP, Arnould L, Moreau L, Chollet P, Weber B, Vanlemmens L, Molucon C, Tubiana N, Causeret S, Misset JL, Feutray S, Mery-Mignard D, Garnier J, Fumoleau P (2006) Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann Oncol 17:409–414

    Article  PubMed  CAS  Google Scholar 

  8. Yaal-Hahoshen N, Safra T (2006) Herceptin (trastuzumab): adjuvant and neoadjuvant trials. Isr Med Assoc J 8:416–421

    PubMed  CAS  Google Scholar 

  9. Chang JC (2007) HER2 inhibition: from discovery to clinical practice. Clin Cancer Res 13:1–3

    Article  PubMed  Google Scholar 

  10. Untch M, von Minckwitz G (2009) Recent advances in systemic therapy: advances in neoadjuvant (primary) systemic therapy with cytotoxic agents. Breast Cancer Res 11:203

    Article  PubMed  Google Scholar 

  11. Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kuhn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, von Minckwitz G (2010) Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 28:2024–2031

    Article  PubMed  CAS  Google Scholar 

  12. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375:377–384

    Article  PubMed  CAS  Google Scholar 

  13. Gonzalez RJ, Buzdar AU, Fraser Symmans W, Yen TW, Broglio KR, Lucci A, Esteva FJ, Yin G, Kuerer HM (2007) Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin). Breast J 13:72–75

    Article  PubMed  CAS  Google Scholar 

  14. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792

    Article  PubMed  CAS  Google Scholar 

  15. Lin C, Chien SY, Chen LS, Kuo SJ, Chang TW, Chen DR (2009) Triple negative breast carcinoma is a prognostic factor in Taiwanese women. BMC Cancer 9:192

    Article  PubMed  Google Scholar 

  16. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368–1376

    Article  PubMed  CAS  Google Scholar 

  17. Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL, Harris JR (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26:2373–2378

    Article  PubMed  Google Scholar 

  18. Rakha EA, Reis-Filho JS, Ellis IO (2008) Basal-like breast cancer: a critical review. J Clin Oncol 26:2568–2581

    Article  PubMed  Google Scholar 

  19. Kurebayashi J, Moriya T, Ishida T, Hirakawa H, Kurosumi M, Akiyama F, Kinoshita T, Takei H, Takahashi K, Ikeda M, Nakashima K (2007) The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast 16(Suppl 2):S72–S77

    Article  PubMed  Google Scholar 

  20. Perreard L, Fan C, Quackenbush JF, Mullins M, Gauthier NP, Nelson E, Mone M, Hansen H, Buys SS, Rasmussen K, Orrico AR, Dreher D, Walters R, Parker J, Hu Z, He X, Palazzo JP, Olopade OI, Szabo A, Perou CM, Bernard PS (2006) Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res 8:R23

    Article  PubMed  Google Scholar 

  21. Adams AL, Eltoum I, Krontiras H, Wang W, Chhieng DC (2008) The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and HER2/neu status in breast carcinoma. Breast J 14:141–146

    Article  PubMed  Google Scholar 

  22. Madarnas Y, Trudeau M, Franek JA, McCready D, Pritchard KI, Messersmith H (2008) Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review. Cancer Treat Rev 34:539–557

    Article  PubMed  CAS  Google Scholar 

  23. D’Alfonso T, Liu YF, Monni S, Rosen PP, Shin SJ (2010) Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed. Am J Surg Pathol 34:575–581

    Article  PubMed  Google Scholar 

  24. Cameron DA (2011) Chemotherapy, trastuzumab, and pathological complete response: when shall we three meet again? J Clin Oncol 29:3344–3346

    Article  PubMed  CAS  Google Scholar 

  25. Untch M, Fasching PA, Konecny GE, Hasmuller S, Lebeau A, Kreienberg R, Camara O, Muller V, du Bois A, Kuhn T, Stickeler E, Harbeck N, Hoss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S (2011) Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 29:3351–3357

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by grants from Sanofi-Aventis Taiwan Co. Ltd. and Roche Taiwan Co. Ltd. Editorial support was provided by Ms. Yu-Fen Wang for editing assistance.

Conflict of interests

None.

Author information

Authors and Affiliations

  1. Comprehensive Breast Cancer Center, Changhua Christian Hospital, 135, Nanhsiao Street, Changhua, 500, Taiwan, ROC

    Che Lin & Dar-Ren Chen

  2. Department of Environmental Engineering, National Chung-Hsing University, Taichung, Taiwan, ROC

    Che Lin

  3. Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan, ROC

    King-Jen Chang

  4. Department of Surgery, National Cheng Kung University Hospital, Tainan, Taiwan, ROC

    Tsai-Wang Chang

  5. Department of Surgery, China Medical University Hospital, Taichung, Taiwan, ROC

    Hwei-Chung Wang

Authors
  1. Che Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dar-Ren Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. King-Jen Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tsai-Wang Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hwei-Chung Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dar-Ren Chen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lin, C., Chen, DR., Chang, KJ. et al. A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin and trastuzumab for T2 breast cancers. Cancer Chemother Pharmacol 69, 1363–1368 (2012). https://doi.org/10.1007/s00280-012-1841-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-012-1841-y

Keywords

Search

Navigation